Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML
Status:
Terminated
Trial end date:
2017-10-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if a medicine called pacritinib is both safe and
effective as a study intervention for patients with AML in combination with either decitabine
or cytarabine. Pacritinib is an experimental drug that is being studied to treat acute
myeloid leukemia (AML). Decitabine and cytarabine are both FDA approved drugs that are used
in treatment of AML. Pacritinib is being tested in clinical trials and has not been submitted
to the U.S. Food and Drug Administration (FDA) for approval for any indications. Pacritinib
is a drug that is designed to slow down the growth of leukemic cells.